Loading...
XHKG
1681
Market cap1.34bUSD
Jul 18, Last price  
12.38HKD
1D
0.98%
1Q
30.87%
Jan 2017
220.73%
IPO
162.29%
Name

Consun Pharmaceutical Group Ltd

Chart & Performance

D1W1MN
P/E
10.60
P/S
3.25
EPS
1.07
Div Yield, %
4.85%
Shrs. gr., 5y
-0.53%
Rev. gr., 5y
11.42%
Revenues
2.97b
+14.56%
457,801,000571,765,000730,683,000831,108,0001,223,488,0001,660,230,0001,843,973,0001,728,256,0001,752,830,0002,044,660,0002,339,650,0002,590,115,0002,967,235,000
Net income
910m
+16.05%
136,206,000152,882,000211,200,000249,689,000307,526,000396,242,000465,353,00079,820,000498,788,000590,172,000682,907,000784,534,000910,458,000
CFO
0k
-100.00%
128,832,000163,610,000294,721,000184,043,000449,177,000252,123,000754,210,000383,315,000867,058,000725,537,000947,679,000818,973,0000
Dividend
Jun 10, 20250.3 HKD/sh

Profile

Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography. The company also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; and Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis. In addition, it offers Gyn Antidysmenorrheic tablets for the treatment of irregular menstruation, irregular period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion for staphylococcus aureus, Candida albicans, and escherichia coli in the feminine vaginal. Further, the company provides bone-setting liquid; Yunxiang analgesic tincture for treatment of rheumatism, common cold, headache, stomachache, cardiodynia, and pain in gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; and Shiduqing capsules and tablets, and Paeonol ointment for skin disease. Additionally, it offers hepatobiliary, gastroenterology, tonics, and other medicines. The company was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
IPO date
Dec 19, 2013
Employees
3,009
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,967,235
14.56%
2,590,115
10.71%
2,339,650
14.43%
Cost of revenue
2,116,123
1,944,777
1,788,741
Unusual Expense (Income)
NOPBT
851,112
645,338
550,909
NOPBT Margin
28.68%
24.92%
23.55%
Operating Taxes
102,732
77,149
62,696
Tax Rate
12.07%
11.95%
11.38%
NOPAT
748,380
568,189
488,213
Net income
910,458
16.05%
784,534
14.88%
682,907
15.71%
Dividends
(326,249)
(127,492)
Dividend yield
8.56%
3.97%
Proceeds from repurchase of equity
14,202
(26,428)
BB yield
-0.37%
0.82%
Debt
Debt current
259,763
507,636
454,229
Long-term debt
21,235
12,014
15,602
Deferred revenue
19,179
18,929
Other long-term liabilities
81,824
Net debt
(3,613,759)
(3,072,784)
(2,576,014)
Cash flow
Cash from operating activities
818,973
947,679
CAPEX
(52,564)
(51,589)
Cash from investing activities
(231,772)
(368,804)
Cash from financing activities
(280,100)
(342,205)
FCF
686,548
579,480
471,662
Balance
Cash
3,865,682
3,583,204
3,039,345
Long term investments
29,075
9,230
6,500
Excess cash
3,746,395
3,462,928
2,928,862
Stockholders' equity
4,393,052
3,983,740
3,522,178
Invested Capital
995,650
986,497
956,358
ROIC
75.51%
58.49%
65.62%
ROCE
17.95%
14.28%
13.90%
EV
Common stock shares outstanding
832,109
799,168
791,997
Price
8.15
70.86%
4.77
17.78%
4.05
-7.95%
Market cap
6,781,688
77.90%
3,812,031
18.84%
3,207,588
-9.41%
EV
3,463,378
1,031,456
925,440
EBITDA
851,112
723,427
627,264
EV/EBITDA
4.07
1.43
1.48
Interest
21,264
10,933
Interest/NOPBT
3.30%
1.98%